ライフサイエンスコーパス: abnormal involuntary movement

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 s syndrome, and various other disorders with abnormal involuntary movements.

2 The development of abnormal involuntary movements (a measure of LID) as wel

3 Symptoms can mimic the full range of organic abnormal involuntary movements, affect gait and speech,

4 nomalies, we examined cylinder behaviour and abnormal involuntary movement (AIM), respectively.

5 opamine rats that developed levodopa-induced abnormal involuntary movements (AIMs) after three weeks

6 Therefore, following induction of abnormal involuntary movements (AIMs), 6-OHDA rats were

7 mediately following the second injection for abnormal involuntary movements (AIMs), analogous to dysk

8 ediate-early genes only in rats experiencing abnormal involuntary movements (AIMs).

9 Total abnormal involuntary movements (AIMs, a measure of LID)

10 levodopa tests, including different types of abnormal involuntary movements and hypersensitivity of r

11 The abnormal involuntary movements associated with this dise

12 generative disorder that is characterized by abnormal involuntary movements (chorea), intellectual im

13 striatum dramatically reduced l-dopa-induced abnormal involuntary movements compared with control mic

14 n ligase parkin PD gene leads to exaggerated abnormal involuntary movements compared with wild-type m

15 Assessments included abnormal involuntary movements, extrapyramidal signs, ps

16 e treatment, is associated with debilitating abnormal involuntary movements or dyskinesias, for which

17 hese values were analyzed in relationship to abnormal involuntary movement ratings.

18 scored with the motor subset of the modified Abnormal Involuntary Movement Scale (AIMS) by raters bli

19 group compared with the placebo group on the Abnormal Involuntary Movement Scale (AIMS) dyskinesia sc

20 The primary efficacy endpoint was change in Abnormal Involuntary Movement Scale (AIMS) score from ba

21 Clinical efficacy was determined using the Abnormal Involuntary Movement Scale (AIMS).

22 The Abnormal Involuntary Movement Scale and research diagnos

23 Movement disorders were assessed with the Abnormal Involuntary Movement Scale and Simpson-Angus Ra

24 atory values, weight, metabolic indices, and Abnormal Involuntary Movement Scale score.

25 Simpson-Angus Scale, Barnes Akathisia Scale, Abnormal Involuntary Movement Scale) were not significan

26 ale for the Assessment of Negative Symptoms, Abnormal Involuntary Movement Scale, and a 40-item side

27 ts included adverse events, vital signs, the Abnormal Involuntary Movement Scale, the Barnes Akathisi

28 ted for tardive dyskinesia symptoms with the Abnormal Involuntary Movement Scale.

29 nvoluntary movements were assessed using the Abnormal Involuntary Movement Scale.

30 blinded assessments performed were clinical (Abnormal Involuntary Movements Scale, Barnes Akathisia S

31 ic rates in the putamen scored higher on the Abnormal Involuntary Movements Scale.

32 ment is complicated by eventual debilitating abnormal involuntary movements termed L-DOPA-induced dys

33 -Angus Scale and the Barnes Akathisia Scale; abnormal involuntary movements were assessed using the A

34 ation exposure, extrapyramidal symptoms, and abnormal involuntary movements were used as covariates.

35 We report that RGS9 knock-out mice develop abnormal involuntary movements when inhibition of dopami

36 The transgenic mice developed abnormal involuntary movements with dystonic-appearing,

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。